In about 10% of human cancers, PP2A is inhibited by genomic mutations, but the most prevalent mechanism for PP2A inhibition in cancer is overexpression of one of the numerous oncogenic PP2A inhibitor proteins such as CIP2A, PME-1, or SET (Kauko & Westermarck, 2018) (Fig 1A). This evidence concerns the gene PTPA and cancer.